Browse Research

In this trial involving patients with IgA nephropathy, sibeprenlimab, a humanized IgG2 monoclonal antibody that blocks a proliferation-inducing ligand, resulted in a greater decrease in proteinuria than placebo.

In a trial involving patients with infrapopliteal artery disease, the use of a drug-eluting resorbable scaffold was superior to angioplasty in reducing reintervention and maintaining patency at 1 year.

In three patients with Alzheimer’s disease, focused ultrasound was applied with aducanumab therapy. Reduction in amyloid was greater in treated regions than in matched contralateral regions over 6 months.

Nirsevimab, a monoclonal antibody targeting RSV, led to decreased hospitalizations for RSV-associated lower respiratory tract infection in infants during their first RSV season, in an open-label, pragmatic trial.

The IARC convened a group of scientists to review the evidence on reduction or cessation of alcohol beverage consumption in relation to alcohol-related cancer incidence or mortality.

In this phase 3 trial involving patients with FSGS, sparsentan resulted in a greater reduction in proteinuria than irbesartan, but there was no significant between-group difference in eGFR slope.

New stroke occurred in 7% of patients who received clopidogrel–aspirin and in 9% who received only aspirin up to 72 hours after atherothrombotic stroke. Bleeding incidence was low but higher with dual antiplatelet treatment.

In patients with myocardial infarction and anemia, a liberal transfusion strategy led to fewer deaths and heart attacks than a restricted transfusion strategy, but the difference was of borderline significance.

In a randomized trial of PCI in patients with stable angina who were receiving little or no antianginal medication and had documented ischemia, PCI resulted in a better health status with respect to angina than placebo at 12 weeks.

Doxycycline postexposure prophylaxis has been shown to prevent STIs in cisgender men and transgender women. In this trial involving cisgender women in Kenya, STI incidence was not lower with doxycycline than with standard care.

This report describes three rare cases of melioidosis (caused by Burkholderia pseudomallei) that were locally acquired in Mississippi.

Tebentafusp is a bispecific molecule that recognizes CD3 and gp100. In a trial in patients with uveal melanoma, median survival at 3 years of follow-up was 21.6 months with tebentafusp and 16.9 months with standard therapy.

In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 months.

In a placebo-controlled, phase 2–3 trial, one dose of mRNA-1345 led to a lower incidence of RSV disease among adults 60 years of age or older. Solicited local and systemic adverse reactions occurred more often with the vaccine.

In a study over two influenza seasons, a high-dose recombinant influenza vaccine was 15% more effective than a standard-dose vaccine in preventing PCR-confirmed influenza in adults between 50 and 64 years of age.

The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma.

Among patients with previously untreated chronic lymphocytic leukemia, ibrutinib–venetoclax therapy with treatment duration guided by measurable residual disease status resulted in better outcomes than standard chemotherapy.